临床试验药物安全性

关键字：类型：

下载页码(大于0,小于852)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

临床试验药物安全性 1506条(本栏目收费,不能显示细节,电话13136136841)

Cilloni study,372,374 372 374

Circulating tumor cells (CTC),405,408 405 408

Cirrhosis,647 647

HCV infections,646,647 646 647

Cisapride,509 509

Cisplatin,573,595 573 595

Cisplatin,black box warning,694,695 694 695

c-Kit,51,100 51 100

Cladribine multiple sclerosis management,620,621 620 621

origins,5,7 5 7

Clinical Hold,754,755,810,811 754 755 810 811

examples,810,811 810 811

FDA’s decision-making process inimposing,811 811

Clinical research associate (CRA),133,530 133 530

Clinical Study Protocol (CSP) amendments,66,68 66 68

inclusion/exclusion criteria,84,85 84 85

ABC transporters,97,98 97 98

Abrial study,178 178

Accelerated approval,806,808,812 813 806,808,812 813

Active control (AC),40,41,43,58,59 40 41 43 58 59

Acute lymphocytic leukemia (ALL),331 331

clinical features,339,340 339 340

cytogenetics for diagnosis and prediction,355,358,375 355 358 375

minimal residual disease,368,374 368 374

Acute myeloid leukemia (AML),331 331

clinical features,343,345 343 345

cytogenetics for diagnosis and prediction,354,355 354 355

Acute promyelocytic leukemia (APL),345,346,374 345 346 374

exemplified by hepatitis C virus,818,820 818 820

oncology,814,815 814 815

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：